Purpose-To evaluate the use of pulsed high-intensity focused ultrasound exposures to improve tissue plasminogen activator (tPA)-mediated thrombolysis in an in vitro model.
Materials and Methods-All experimental work was compliant with institutional guidelines andHIPAA. Clots were formed by placing 1 mL of human blood in closed-off sections of pediatric Penrose tubes. Four experimental groups were evaluated: control (nontreated) clots, clots treated with pulsed high-intensity focused ultrasound only, clots treated with tPA only, and clots treated with pulsed high-intensity focused ultrasound plus tPA. The focused ultrasound exposures (real or sham) were followed by incubations of the clots in tPA with saline or in saline only. Thrombolysis was measured as the relative reduction in the mass of the clot. D-Dimer assays also were performed. Two additional experiments were performed and yielded dose-response curves for two exposure parameters: number of pulses per raster point and total acoustic power. Radiation force-induced displacements caused by focused ultrasound exposures were simulated in the clots. A Tukey-Kramer honestly significant difference test was performed for comparisons between all pairs of experimental groups.Results-The clots treated with focused ultrasound alone did not show significant increases in thrombolysis compared with the control clots. The clots treated with focused ultrasound plus tPA showed a 50% ([30.2/20.1]/20.1) increase in the degree of thrombolysis compared with the clots treated with tPA only (P < .001), further corroborating the D-dimer assay results (P < .001). Additional experiments revealed how increasing both the number of pulses per raster point and the total acoustic power yielded corresponding increases in the thrombolysis rate. In the latter experiment, simulations performed at a range of power settings revealed a direct correlation between increased displacement and observed thrombolysis rate.Conclusion-The rate of tPA-mediated thrombolysis can be enhanced by using pulsed highintensity focused ultrasound exposure in vitro.Venous thromboembolism, which includes deep venous thrombosis and pulmonary embolism, accounts for about 250 000 hospitalizations per year in the United States (1). Venous Address correspondence to V.F. (e-mail: vfrenkel@cc.nih.gov For decades patients with venous thrombosis have been treated primarily with anticoagulation, which is usually effective at slowing further thrombus formation. However, anticoagulation is often inadequate for eliminating the source of subsequent emboli, alleviating the hemodynamic disturbances, preventing subsequent valvular damage, and preventing permanent impairment to the pulmonary vascular bed (3). For this reason, more aggressive therapy, such as thrombolysis or thrombectomy, is sometimes used.Ultrasound has been studied as a treatment adjunct to thrombolytic drugs for thrombolysis, as well as an independent treatment method in various models (4-9). Catheter-based systems have been used with oscillating wires to ...